About
Information is our nourishment. Say hello to the data gods.
Meet Our Team
Consumers speak. We listen, analyze, and dig deep. You win!
Learn More
Solutions
Get targeted insights into industry trends with our quarterly sector reports, so you can predict the future and stay a step ahead.
Learn More
Receive alerts and reports to power your fund management. Partner with our team of analysts to take your research to the next level.
Learn More
Plug our consumer-demand-data directly into your client-facing software, tools, and platform or work with us to create custom, high-value content your customers will love.
Learn More
Testing our data is like jumping in a time machine to compare market gains and losses against reliable and annotated historical data.
Learn More
Track specific tickers, receive alerts, and watch sector-specific trends. Drill down on individual stocks and see where consumer sentiment aligned with gains and losses in trading.
Learn More
Who We Serve
LikeFolio is your real-time focus group keeping you connected to consumers and giving you a critical edge over your competition.
Learn More
LikeFolio is your research secret weapon to sniff out game-changing shifts in the market before they happen.
Learn More
LikeFolio is source of quantitative data based upon real consumer insights to power your investment engine.
Learn More
LikeFolio is your content pipeline positioning your tool as an indispensable resource to your customers.
Learn More
LikeFolio has partnered with Tradesmith to build Derby City Insights and bring our powerful insights engine to private investors.
Learn More

How Big is Altria’s Juul Problem?

Altria is one of our “Sin Stocks” to watch… 

Demand for the tobacco products company is trending +16% QoQ and +21% YoY.

However, it’s run into a problem.

The FDA confirmed Thursday that it has issued marketing denial orders for its products in the US, meaning it must stop selling and distributing its products.

Juul has faced heightened scrutiny for a few years over its marketing of nicotine products and their appeal to teenagers.

After delaying their decision on Juul products in May to look at the public health impacts, the FDA has reportedly decided to order Juul’s e-cigarettes off of shelves in the US.

Altria, which owns a 35% stake in the vaping product's maker, tumbled 9.2% in response. 

The tobacco company invested a hefty $12.8 billion in Juul in 2018.

But that has since plummeted with the estimated fair value of Altria’s investment in Juul at the end of March being $1.6 billion.

The decrease in Q1 was recorded as a pre-tax unrealized loss of $100 million (or $0.05 per share).

In 2018, Juul was said to be generating an annual revenue of around $2 billion. 

However, lawsuits and awareness regarding the dangers of e-cigarettes have seen the company lose significant market share since then, and it reportedly recorded a net loss of $259 million in 2021, with net sales falling to $1.3 billion.

The decision by the FDA will likely be appealed by Juul, with its products remaining on the market until the outcome of that appeal…

So in the meantime, here’s what we will be watching: 

Vaping Mentions Climb Again

report by News In Health stated that about 37% of 12th graders reported vaping in 2018, compared with 28% in 2017.

However, after an initial surge in the latter part of 2020, caused by an outbreak of lung injuries associated with vaping products, mentions quickly fell.

Even so, 2021 saw another uptick, which has followed through to this year.

Juul Demand

The demand decline and loss of market share is easily visualized through Purchase Intent Mentions which are trending at -4% YoY. 

However, unlike vaping mentions, they are still nowhere near the highs of 2019. 

If the FDA comes to the same conclusion after the potential Juul appeal, it would be catastrophic for the company’s already dwindling market share. 

Bottom Line: In truth, it looks as though Altria’s investment in Juul has been a mistake. Juul’s trouble with regulators and heightened scrutiny mean Altria has always been fighting against the tide. 

While there is still hope in the form of a potential appeal, Juul’s market share has tumbled since Altria made its initial investment. 

Nevertheless, if there is a change of heart by the FDA, we will be watching to see if/how consumer demand for Juul products alters.

Related Posts

Related Posts

Related Reports

KEEP YOUR COMPETITIVE EDGE

Get FREE insights in your inbox every week with the Daily Drop.

About LikeFolio

LikeFolio analyzes social media data to accurately predict shifts in consumer behavior. We sell data and insights to professional investors, corporate research teams, and software providers.

Partner Sites

©2022 LikeFolio. All Rights Reserved.
Privacy Policy
|
Terms of Use
LikeFolio userslaptop-phonepie-chartchart-barsselect